The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
Open accessAbstract
Osteoblastic bone metastases are common in prostate and breast cancer patients, but mechanisms by which tumor cells stimulate new bone formation are unclear. We identified three breast cancer cell lines that cause osteoblastic metastases in a mouse model and secrete endothelin-1. Tumor-produced endothelin-1 stimulates new bone formation in vitro and osteoblastic metastases in vivo via the endothelin A receptor. Treatment with an orally active endothelin A receptor antagonist dramatically decreased bone metastases and tumor burden in mice inoculated with ZR-75-1 cells. Tumor-produced endothelin-1 may have a major role in the establishment of osteoblastic bone metastases, and endothelin A receptor blockade represents effective treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,774
Self-citationYin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986
Self-citationThalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 801
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
Levin, E. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330607 · Cited by 711
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Metastatic prostate cancer in a transgenic mouse.
Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., & Greenberg, N. M. (1996) · PubMed · Cited by 599
The endothelin axis: emerging role in cancer
Nelson, J., Bagnato, A., Battistini, B., & Nisen, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc990 · Cited by 564
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Self-citationSalani, D., Taraboletti, G., Rosanò, L., Di Castro, V., Borsotti, P., Giavazzi, R., & Bagnato, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64807-9 · Cited by 341
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson, J. B., Chan‐Tack, K. M., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996) · PubMed · Cited by 333
Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12297-0 · Cited by 211
Self-citationCorey, E., Quinn, J. E., Bladou, F., Brown, L. G., Roudier, M. P., Brown, J. M., Buhler, K. R., & Vessella, R. L. (2002) · The Prostate · doi:10.1002/pros.10091 · Cited by 192
Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma
Salani, D., Di Castro, V., Nicotra, M. R., Rosanò, L., Tecce, R., Venuti, A., Natali, P. G., & Bagnato, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64791-8 · Cited by 189
Yi, B., Williams, P. J., Niewolna, M., Wang, Y., & Yoneda, T. (2002) · PubMed · Cited by 172
Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò, L., Varmi, M., Salani, D., Castro, V. D., Spinella, F., Natali, P. G., & Bagnato, A. (2001) · PubMed · Cited by 161
New therapeutics that antagonize endothelin: promises and frustrations
Remuzzi, G., Perico, N., & Benigni, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd962 · Cited by 160
Carducci, M. A., Nelson, J. B., Kathy Bowling, M., Rogers, T., Eisenberger, M. A., Sinibaldi, V., Donehower, R., Leahy, T. L., Carr, R. A., Isaacson, J. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.028 · Cited by 159
Self-citationBufalo, D. D., Castro, V. D., Biroccio, A., Varmi, M., Salani, D., Rosanò, L., Trisciuoglio, D., Spinella, F., & Bagnato, A. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.524 · Cited by 142
Alam, A. S. M. T., Gallagher, A. C., Shankar, V. S., Ghatei, M. A., Datta, H. K., Huang, C. L.-H., Moonga, B. S., Chambers, T. J., Bloom, S. R., & Zaidi, M. (1992) · Endocrinology · doi:10.1210/endo.130.6.1597159 · Cited by 129
Asham, E., Shankar, A. I., Loizidou, M., Fredericks, S., Miller, K., Boulos, P. B., Burnstock, G., & Taylor, I. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2193 · Cited by 116
Endothelin-1 Is a Potent Regulator of Human Bone Cell Metabolism In Vitro
Kasperk, C. H., Börcsök, I., Schairer, H. U., Schneider, U., Nawroth, P. P., Niethard, F. U., & Ziegler, R. (1997) · Calcified Tissue International · doi:10.1007/s002239900245 · Cited by 91
Yorimitsu, K., Moroi, K., Inagaki, N., Saito, T., Masuda, Y., Masaki, T., & Seino, S. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1397 · Cited by 50
Kozawa, O., Kawamura, H., Hatakeyama, D., Matsuno, H., & Uematsu, T. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00061-9 · Cited by 37
Kitano, Y., Kurihara, H., Kurihara, Y., Maemura, K., Ryo, Y., Yazaki, Y., & Harii, K. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.2.237 · Cited by 36
Detection and Characterization of Endothelin in Transformed Human Osteoblast Cell Culture Medium
Lam, H., Lee, J., & Lai, K.-H. (2000) · Endocrine · doi:10.1385/endo:12:1:77 · Cited by 7
Cited by
Cancer to bone: a fatal attraction
Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3055 · Cited by 1,285
Self-citationThe molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Self-citationBasic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases
Guise, T. A., Mohammad, K. S., Clines, G., Stebbins, E. G., Wong, D. H., Higgins, L. S., Vessella, R., Corey, E., Padalecki, S., Suva, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1007 · Cited by 539
Self-citationThe BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A. H., & Giancotti, F. G. (2012) · Cell · doi:10.1016/j.cell.2012.06.035 · Cited by 430
Metadata
- Authors
- Yin, J. J., Mohammad, K. S., Käkönen, S. M., Harris, S., Wu-Wong, J. R., Wessale, J. L., Padley, R. J., Garrett, I. R., Chirgwin, J. M., & Guise, T. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-08-26
- Volume
- 100
- Issue
- 19
- Pages
- 10954-10959
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2023659903
- Cited by
- 381
- References
- 27
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.